{"entity":{"id":"nct07558733","kind":"trial","name":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of Serabelisib, Sapanisertib and Fulvestrant in advanced solid tumours, run by Faeth Therapeutics, now recruiting.","summary":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT07558733 by Faeth Therapeutics, with 32 participants planned, started 2026-04-22 and due to reach its primary completion in 2029-05. Interventions recorded: Serabelisib, Sapanisertib and Fulvestrant.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07558733","url":"https://clinicaltrials.gov/study/NCT07558733"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["serabelisib","sapanisertib","fulvestrant"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07558733","phase":"1/2","setting":"Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer","sponsor":"Faeth Therapeutics","enrolled":32,"outcomes":[]},"route":"/trials/nct07558733/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"sapanisertib","kind":"drug","name":"Sapanisertib","route":"/drugs/sapanisertib/"},{"id":"serabelisib","kind":"drug","name":"Serabelisib","route":"/drugs/serabelisib/"}]}}